About Contact Us Careers

Buprenorphine Market Size & Share, by Route of Administration (Sublingual, Transdermal, Buccal); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 3193
  • Published Date: Dec 26, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Buprenorphine Market size was valued at USD 6.22 billion in 2024 and is expected to reach USD 35.75 billion by 2037, expanding at around 14.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of buprenorphine is assessed at USD 6.98 billion.

The growth of the market can be attributed to the growing prevalence of chronic pain disorders, increasing occurrence of cancer. According to the World Health Organization (WHO), cancer is the leading cause of deaths worldwide, accounting to about 10 million deaths in the year 2020. In addition to these, escalating government investments in healthcare in developed nations and rising usage of buprenorphine patches as an effective treatment mode is also anticipated to drive market growth in the coming years. Furthermore, the growing dependency on painkillers has led to opioid addiction to many people around the world, which in turn is projected to provide lucrative opportunities to significantly raise the demand for buprenorphine in the near future.

Global-Buprenorphine-Market-Overview
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Increasing Occurrence of Chronic Pain Disorders
  • Rising Healthcare Expenditure in Developed Nations

Challenges

  • Adverse Health Effects Associated with the Use of Buprenorphine

Buprenorphine Market: Key Insights

Report Attribute Details

Base Year

2024

Forecast Year

2025-2037

CAGR

14.4%

Base Year Market Size (2024)

USD 6.22 billion

Forecast Year Market Size (2037)

USD 35.75 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Buprenorphine Segmentation

The market is segmented by route of administration into sublingual, transdermal, and buccal, out of which, the sublingual segment is anticipated to hold the largest share in the buprenorphine market on account of the increasing availability of buprenorphine drugs in several dosages in the sublingual form. Along with this, rapid drug absorption, first-pass metabolism and quick onset of action of sublingual route of administration are also predicted to boost the growth of the market segment in the forecast period. Additionally, the segment for buccal dosage is expected to witness notable growth in the future, which can be credited to the increasing number of people opting for oral drugs as compared to injection-based drugs.

Our in-depth analysis of the global market includes the following segments

 

              By Route Of Administration

 
  • Sublingual
  • Transdermal
  • Buccal

              By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Buprenorphine Industry - Regional Synopsis

North America Market Statistics

On the basis of geographical analysis, the market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is set to account for largest revenue share by 2037, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region. As per the data by National Institute of Drug Abuse, 21 to 29 percent of patients misuse the opioids prescribed for chronic pain. Amongst these, 8-12% people develop an opioid use disorder. Apart from these, high number of cases of abuse related to drugs such as heroin and cocaine is also anticipated to drive the region’s market growth in the forthcoming years.

Europe Market Analysis

Europe is also expected to acquire a notable share in the market owing to the large number of new medical product launches in the region. Moreover, the market in Asia Pacific is projected to witness noteworthy growth during the forecast period ascribing to the rising patient pool and growing awareness about the health benefits of buprenorphine in the region.

Global-Buprenorphine-Market-Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Companies Dominating the Buprenorphine Landscape

    • The Siegfried Group, LLP
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson Matthey Group
    • Purdue Pharma LP
    • Pharmaforce Inc.
    • Hikma Pharmaceuticals PLC
    • Bedford Laboratories
    • Sun Pharmaceutical Industries Ltd.
    • Pfizer, Inc.
    • Neon Laboratories Ltd.
    • Unichem Laboratories

Recent Developments

·    June 2021: Purdue Pharma LP announced that FDA accepted and filing of the abbreviated new drug application for vial dosage form of nalmefene hydrochloride injection, which is designed to treat opioid overdose.

·    May 2020: Hikma Pharmaceuticals PLC launched Buprenorphine Hydrochloride Injection, 0.3mg/mL in the United States through its American affiliate

  • Report ID: 3193
  • Published Date: Dec 26, 2024
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of buprenorphine is assessed at USD 6.98 billion.

Buprenorphine Market size was valued at USD 6.22 billion in 2024 and is expected to reach USD 35.75 billion by 2037, expanding at around 14.4% CAGR during the forecast period i.e., between 2025-2037.

North America industry is set to account for largest revenue share by 2037, on the back of strong presence of market players and growing percentage of the population suffering from opioid dependency in the region.

The major players in the market are The Siegfried Group, LLP, Johnson Matthey Group, Purdue Pharma LP, Pharmaforce Inc., Hikma Pharmaceuticals PLC, and others.

Buprenorphine Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Get a Free Sample

See how top U.S. companies are managing market uncertainty — get your free sample with trends, challenges, macroeconomic factors, charts, forecasts, and more.

Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos